Skip to main content

Table 5 Treatment-Emergent Adverse Events Reported by ≥5% of Subjects in Any Treatment Group

From: A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects

 

FKB327 vial

n = 66

n (%)

FKB327 PFS

n = 63

n (%)

FKB327 AI

n = 66

n (%)

Total

n = 195

n (%)

Nasopharyngitis

14 (21.2)

15 (23.8)

20 (30.3)

49 (25.1)

Headache

7 (10.6)

9 (14.3)

2 (3.0)

18 (9.2)

Cough

5 (7.6)

1 (1.6)

3 (4.5)

9 (4.6)

Oropharyngeal pain

4 (6.1)

3 (4.8)

1 (1.5)

8 (4.1)

Injection-site rash

0

0

4 (6.1)

4 (2.1)

  1. AI indicates prefilled autoinjector; PFS prefilled syringe; vial, vial with disposable syringe